Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Robin Kate Kelley et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
ALKBH5 Regulates m6A Methylation-modified Pre-miR-21 to Promote Lung Injury in Obstructive Sleep Apnea Rat ModelZhijuan Liu, Li Ai|Research Square|2021Cited by 1